(Q34487427)

2 August 2017

1 reference

title

Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? (English)

1 reference

stem cell transplantation

2 August 2017

main subject

1 reference

1 reference

Sweetenham JW

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

Bone Marrow Transplantation

2 August 2017

published in

1 reference

2 August 2017

volume

28

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

813-820

1 reference

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Mantle-cell lymphoma: a population-based clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Patterns of survival in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

CNS involvement in mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Autologous hematopoietic stem cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Allogeneic bone marrow transplantation for refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703255

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703255

1 reference

Dimensions Publication ID

2 August 2017

1036653571

0 references

1 reference